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To the Editor, 
 
 
We have read with interest the review by Ryken et al. [1] about the role of imaging in the 
management of progressive glioblastoma. In general, we agree with this review but we cannot 
support the opinion that the routine use of Positron-Emission-Tomography (PET) to identify 
progression of glioblastoma is not recommendable. 
 
The authors have considered PET using the amino acid tracer 11C-methyl-L-methionine 
(MET), but the use of MET is limited to PET centers with an on-site cyclotron due the short 
half-life of 11C (20.4 min). In recent years, the clinical application of 18F-labeled amino acids 
such as O-(2-18F-fluoroethyl)-L-tyrosine (FET) or 3,4-dihydroxy-6-[18F]fluoro-L-
phenylalanine (FDOPA) has spread considerably due to the logistical advantages of the 18F 
label (half-life, 109.8 min) [2]. FET can be produced with high yields similar to the widely 
used FDG and distributed in a satellite concept. In Europe, MET PET has been replaced in 
many centers by the more convenient PET tracer FET, which is now established as a routine 
tool for brain tumor imaging in more than 30 neurooncological centers in Germany, Austria 
and Switzerland. In these countries, the clinical acceptance is high and we estimate that more 
than 10.000 PET scans using FET have been performed in brain tumor patients during the last 
5 years.  
 
The diagnostic accuracy of FET PET in the differentiation of tumor progression orrecurrence 
from radiation-induced changes is convincing. A sensitivity and specificity of FET PET for 
the detection of tumor progression or recurrence of 100% and 93%, respectively, has been 
reported, compared with 93% and 50% for MRI alone [3, 4]. The additional use of dynamic 
FET PET allows a differentiation of high-grade and low-grade recurrences with a sensitivity 
and specificity of > 90% [5]. Similar results have also been reported for the differentiation of 
recurrent brain metastases from radiation-induced changes with an accuracy of 93% [6]. 
Furthermore, a prospective study evaluated the prognostic value of early changes of FET 
uptake after postoperative radiochemotherapy in patients with glioblastoma [7, 8]. PET 
responders with a decrease of the tumor/brain ratio of more than 10% had a significantly 
longer disease-free survival and overall survival than patients with stable or increasing tracer 
uptake after RCx. Additionally, a reliable treatment monitoring was also demonstrated in 
various experimental approaches (e.g., radioimmunotherapy, convection enhanced delivery of 
paclitaxel) and for antiangiogenic treatment with bevacizumab and irinotecan [7-12].  
 
Using FDOPA PET, a recent study including 110 patients reported an accuracy of 82% to 
detect recurrent glioblastoma and FDOPA uptake was a significant predictor of progression-
free survival [13]. Excellent results with FDOPA PET were also reported regarding the 
monitoring of antiangiogenic treatement [14] and for the differentiation of recurrent brain 
metastases from radiation-induced changes [15].  
 
Moreover, we would like to point out that the excellent results of SPECT with respect to 
differentiation of tumor recurrence mentioned in the review of Ryken et al. is based on the use 
of the amino acid tracer IMT [16], which delivers similar results as FET PET but at lower 
spatial resolution [17].  
 
In summary, we consider PET using 18F-labelled amino acids such as FET or FDOPA as one 
of the most promising imaging methods in the management of progressive glioblastoma. In 
the review by Ryken and colleagues, this recent development has not been adequately 
addressed.   
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